HCPCS Level II code J9305 designates a 10 mg unit of pemetrexed for injection, an antineoplastic agent commonly used in oncology care. As a unit-based drug code, J9305 is significant for national chemotherapy billing, inventory management, and payer payment policies because it defines how pemetrexed is reported on outpatient and infusion service lines.

Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national perspective on clinical context, typical sites of service, and the role of unit-based HCPCS reporting for pemetrexed. The publication outlines what to expect in benchmarks and payment policy considerations at a national level and clarifies the service classification for claims and billing teams.

This document is intended to inform coding, billing, and revenue cycle stakeholders about how J9305 is used on service lines, where the service is typically delivered, and which major payers are relevant for national policy and coverage considerations. Data not provided in the input are noted explicitly where applicable.